Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CES2 | O00748 | 2/20 | 0.50 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | XBP1 | P17861 | 1/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.41 |
| ▸ | PTPN5 | P54829 | 1/20 | 0.39 |
| ▸ | PDE2A | O00408 | 2/20 | 0.38 |
| ▸ | TSHR | P16473 | 2/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.37 |
| ▸ | TAS2R14 | Q9NYV8 | 1/20 | 0.36 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.35 |
| ▸ | PTPN6 | P29350 | 1/20 | 0.35 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | KIF11 | P52732 | 2/20 | 0.34 |
| ▸ | NOS3 | P29474 | 1/20 | 0.34 |
| ▸ | NOS2 | P35228 | 1/20 | 0.34 |
| ▸ | PKM | P14618 | 1/20 | 0.34 |
| ▸ | BACE1 | P56817 | 1/20 | 0.34 |
| ▸ | GPR3 | P46089 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29454603 | 1.00 | CES2 (0.50) | CES2NOTUMMAPTXBP1NPSR1 | |
| SCHEMBL13940346 | 0.85 | NOTUM (0.46) | CES2NOTUMMAPTXBP1NPSR1 | |
| SCHEMBL12732888 | 0.85 | KIF11 (0.43) | CES2NOTUMMAPTXBP1NPSR1 | |
| SCHEMBL29632676 | 0.81 | MAPT (0.53) | CES2NOTUMMAPTXBP1NPSR1 | |
| SCHEMBL496276 | 0.81 | MAPT (0.53) | CES2NOTUMMAPTXBP1NPSR1 | |
| SCHEMBL7863398 | 0.80 | PTPN5 (0.41) | CES2MAPTXBP1NPSR1PTPN5 | |
| SCHEMBL29637726 | 0.80 | PTPN5 (0.41) | CES2MAPTXBP1NPSR1PTPN5 | |
| SCHEMBL22140267 | 0.78 | PDE2A (0.38) | CES2NOTUMMAPTXBP1NPSR1 | |
| SCHEMBL672252 | 0.78 | NOTUM (0.47) | CES2NOTUMTSHRMAPK1ALDH1A1 | |
| SCHEMBL6061078 | 0.77 | CES2 (0.56) | CES2NOTUMPTPN5PDE2ATSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 176 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3543319-A1 | METHOD OF MARKING HYDROCARBON LIQUIDS | Johnson Matthey Public Limited Company (GB) | 2019-09-25 | — | — | EP | claimed |
| US-20140120626-A1 | METHOD OF MARKING HYDROCARBON LIQUIDS | JOHNSON MATTHEY PUBLIC LIMITED COMPANY (GB) | 2014-05-01 | — | — | US | claimed |
| EP-2707465-A1 | METHOD OF MARKING HYDROCARBON LIQUIDS | Johnson Matthey Public Limited Company (GB) | 2014-03-19 | — | — | EP | claimed |
| US-8512935-B2 | Functionalized perfluoropolyether material as a hydrophobic coating | HEWLETT-PACKARD DEVELOPMENT COMPANY, L.P. (US) | 2013-08-20 | — | — | US | claimed |
| WO-2012153132-A1 | METHOD OF MARKING HYDROCARBON LIQUIDS | JOHNSON MATTHEY PUBLIC LIMITED COMPANY (GB) | 2012-11-15 | — | — | WO | claimed |
| US-4079090-A | Preparation of trichloromethyl-trifluoro methyl-benzenes | BAYER AKTIENGESELLSCHAFT (DT) | 1978-03-14 | — | — | US | claimed |
| EP-3433239-B1 | SMALL MOLECULE INHIBITORS OF THE NUCLEAR TRANSLOCATION OF ANDROGEN RECEPTOR FOR THE TREATMENT OF CASTRATION-RESISTANT PROSTATE CANCER | UNIV PITTSBURGH COMMONWEALTH SYS HIGHER EDUCATION (US) | 2026-05-27 | — | — | EP | disclosed |
| EP-3558298-B1 | ANTIDIABETIC SPIROCHROMAN COMPOUNDS | MERCK SHARP & DOHME LLC (US) | 2026-03-11 | — | — | EP | disclosed |
| US-12570803-B2 | Composition, silicone polyether surfactant formed therefrom, and related methods and articles | DOW SILICONES CORPORATION (US) | 2026-03-10 | — | — | US | disclosed |
| US-12473404-B2 | Composition and method for silyl hydride reaction catalyzed by fluorinated arylborane Lewis acids | DOW GLOBAL TECHNOLOGIES LLC (US) | 2025-11-18 | — | — | US | disclosed |
| US-12441844-B2 | Methods for making polyfunctional organosiloxanes and compositions containing same | DOW GLOBAL TECHNOLOGIES LLC (US) | 2025-10-14 | — | — | US | disclosed |
| EP-3856811-B1 | POLYURETHANES AND METHOD FOR MAKING POLYURETHANES | DOW GLOBAL TECHNOLOGIES LLC (US) | 2025-09-10 | — | — | EP | disclosed |
| US-12398241-B2 | Composition and method for reacting an organosilicon compound and a silyl hydride catalyzed by a fluorinated arylborane Lewis acid | DOW GLOBAL TECHNOLOGIES LLC (US) | 2025-08-26 | — | — | US | disclosed |
| WO-2002003978-A2 | A COMBINATION OF FBPase INHIBITORS AND ANTIDIABETIC AGENTS USEFUL FOR THE TREATMENT OF DIABETES | METABASIS THERAPEUTICS, INC. (US) | 2002-01-17 | — | — | WO | disclosed |
| US-6326517-B1 | REACTIN AN AROMATIC COMPOUND WITH CARBON MONOXIDE AND AMMONIA | CENTRAL GLASS COMPANY, LIMITED (JP) | 2001-12-04 | — | — | US | disclosed |
| WO-2001066553-A2 | NOVEL ARYL FRUCTOSE-1,6-BISPHOSPHATASE INHIBITORS | METABASIS THERAPEUTICS, INC. (US) | 2001-09-13 | — | — | WO | disclosed |
| US-6268527-B1 | REACTING TRIFLUOROMETHYL SUBSTITUTED AROMATIC COMPOUND WITH CARBON MONOXIDE AND HYDROXY COMPOUND IN PRESENCE OF METAL COMPOUND AND PHOSPHINE DERIVATIVE TO PRODUCE TRIFLUOROMETHYL SUBSTITUTED BENZOIC ACID DERIVATIVE | CENTRAL GLASS COMPANY, LIMITED (JP) | 2001-07-31 | — | — | US | disclosed |
| US-5877191-A | ANTIINFLAMMATORY AGENT; ANALGESICS; ANTIHISTAMINES; EMESIS | MERCK & CO., INC. (US) | 1999-03-02 | — | — | US | disclosed |
| WO-1998017660-A1 | PHENYL SPIROETHERCYCLOALKYL TACHYKININ RECEPTOR ANTAGONISTS | MERCK & CO., INC. (US) | 1998-04-30 | — | — | WO | disclosed |
| US-4079090-A | Preparation of trichloromethyl-trifluoro methyl-benzenes | BAYER AKTIENGESELLSCHAFT (DT) | 1978-03-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12570803-B2 | Composition, silicone polyether surfactant formed therefrom, and related methods and articles | SGMS2, SGMS1, MSR1 | CES2 827/4885NOTUM 24/4885MAPT 4814/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.